Zhenlin Li

Partner at Photon Fund

📍 San Francisco Bay Area, United States🔄 Updated October 2026💼 2 investments📅 8 years investing🗓 Last invested Aug 2018
VC🌍 United States
2
Total investments
0
Early stage
1
Mid stage
0
Late stage
8y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Aug 2018
Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.
Board Observer
Mar 2018
Nelumbo is commercializing a new platform of structural materials. The company’s current focus is on developing improved heat exchangers for the HVAC market. Our ability to improve energy performance and minimize corrosion in a single platform unlocks mass market opportunity with potential for significant carbon emission and energy use reductions worldwide.
Experience · 8 entries
All (8)
Investments (2)
Founder (1)
Board (2)
2019
Member
May 2019
Life Science Angels (LSA) is the premier angel investing organization in the US, focused on investing exclusively in the life sciences. Since 2005, LSA has invested in 100+ companies in medical technology and biotechnology investment opportunities.
2018
Board Observer
Aug 2018
Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.
Board Observer
Mar 2018
Nelumbo is commercializing a new platform of structural materials. The company’s current focus is on developing improved heat exchangers for the HVAC market. Our ability to improve energy performance and minimize corrosion in a single platform unlocks mass market opportunity with potential for significant carbon emission and energy use reductions worldwide.
Photon Fund
Partner at Photon Fund
Mar 2018
2017
Photon Fund
Managing Director
Oct 2017
Show all 8 entries ↓